- What is a clinical trial?
A clinical trial is a research study that explores whether a treatment, medication, or device is safe and effective for humans. These studies look to provide information about potential side-effects of specific treatments and which medical interventions work best for specific illnesses or groups of people.
- The importance of clinical trials
Clinical trials provide information about the safety and effectiveness of new approaches to see if they should become widely available. Most of the standard cancer treatments used today were first shown to be effective through clinical trials.
There are many reasons why someone may choose to take part in a clinical trial.
You may gain access to new medications, treatments or devices, which may be beneficial to your health. You may receive care specific to the clinical trial, which may include additional testing and/or more frequent follow-up with the medical staff for the condition being studied. You will help others by contributing to medical research and treatment advances. You may have the opportunity to gain additional knowledge about your own medical condition.
- Clinical trials at MSH
Currently Markham Stouffville Hospital is participating in the following trials:Study Title: A Pragmatic Cluster-Randomized Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer (AToM)
Researcher: Dr Leena Hajra
ClinicalTrials.gov Identifier: NCT02485678 Study Title: Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial (AVERT Trial)
Researcher: Dr Mateya Trinkaus
ClinicalTrials.gov Identifier: NCT02048865
Patients who are interested in participating in a clinical trial, should speak with their oncologist.
Watch a video about clinical trials at MSH.
- Additional resources
For more information about clinical trials at MSH, please contact the oncology clinical trials office at 905-472-7373 ext.2021.